HRGN Stock Price, Chart, Stats & News

Harvard Apparatus Regenerative Technology Inc.
Save
Harvard Apparatus Regenerative Technology Inc. (HRGN) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
HRGN chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease.
Similar securities
Based on sector and market capitalization
Report issue





